Genetic mutation in thrombophilic Egyptian patients

Journal of Medical Sciences

Volumn 6, Issue 4, 2006, Pages 591-596

  Hasan, Nehal Salah ^a   El Din, Hesham Gamal ^a   Awad, Mona Abd El Kader ^a   Aisha, Hesham Abou ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

APCR; DVT; Factor V Leiden; PAI 1; Thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA DETERMINATION; EGYPT; FEMALE; FIBRINOLYSIS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; HOMOZYGOSITY; HUMAN; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOPHILIA;

EID: 33750368817     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2006.591.596     Document Type: Article

References (39)

1. Bertina, R.M., B.P. Koeleman, T. Koster, F.R. Rosendaal, R.J. Dirven, H. de Ronde, van der P.A. Valden and P.H. Reitsma, 1994. Mutation in blood coagulation in factor V associated with resistance to activated protein C. Nature, 369: 64-67.
2. Bertina, R.M., 1997. Factor V Leiden and other coagulation factor mutations affecting tbrombotic risk. Clin. Chem., 43: 1678-1683.
3. Brown, R. and E. Yuen, 2005. Deep venous thrombosis (DVT)-factor V Leiden and prothrombin G20210A point mutations-Issue 34. Instituate of Haematology, RPAH CSLS Newsletter CSAHS April 2005 [www.cs.nsw.gov.au/ csls/handbook/newsletterveiw.asp]
4. Buyru, N., J. Altinisik, G. Somay and T. Ulutin, 2005. Factor V Leiden mutation in cerebrovascular disease. Clin. Applied Tbromb. Hemost., 11: 339-342.
5. Dahlback, B., M. Carlsson and P.J. Svensson, 1993. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor of protein C. Proc. Natl. Acad. Sci. USA., 90: 1004-1008.
6. Dawson, S.J., B. Wiman, A. Hamsten, F. Green, S. Humphries and A.M. Henney, 1993. The two alleles sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin in HepG2 cells. J. Biol. Chem., 268: 10739-10745.
7. Doggen, C.J.M., R.M. Bertina, F.R. Rosendaal and H.L. Vos, 2004. Study of myocardial infarction Leiden. Leiden University Medical Center. Thrombosis and Haemostasis research center [www.lumc.nl/4060/research/ smile.html].
8. Eichinger, S., A. Weltermann, C. Mannhalter, E. Minar, C. Bialonczyk, M. Hirschl, V. Schonauer, K. Lechner P.A. Kyrle, 2002. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch. Intl. Med., 162: 2357-2360.
9. Eid, S.S., 2002. Hereditary deficiencies of antithrombin III, protein S and the protein C pathway in Jordanian thrombosis patients. Clin. Lab. Sci. Fall., 15: 196-199.
10. Elmer, S., S. Jan, P. Edmund, S. Karl and M. Siegfried, 2005. Recurrent thrombotic occlusion of a transjugular intrahepatic portosystemic stent-shunt due protein C resistance. World J. Gastroenterol, 28: 5064-5067.
11. Emmerich, J. and M. Aiach, 2002. Genetic risk factors of thrombosis. Ann. Cardiol. Angeiol. Paris, 51: 129-134.
12. Erikson, P., B. Kallin, F. van't Hooft, P. Bavenholm and A. Hamsten, 1995. Allele specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction. Proc. Nalt. Acad. Sci. USA., 92: 1851-1855.
13. Fisher, M., A.A. Fernandez and S.F. Amerisco, 1996. Activated protein C resistance in ischemic stroke not due to factor V arginine 506: Glutamine mutation. Stroke, 27: 1163-1166.
14. Francis, C.W., 2002. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch. Pathol. Lab. Med., 126: 1401-1404.
15. Galli, M., D. Luciani, G. Bertolini and T. Barbui, 2003. Lupus anticoagulant are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome. Blood, 101: 1827-1832.
16. Gerhardt, A., T.W. Goecke, M.W. Beckmann, K.J. Wagner, B. Tutschek, R. Willers, H.G. Bender, R.E. Scharf and R.B. Zotz, 2005. The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J. Thromb. Haemost., 3: 686-691.
17. Gils, A., J.M. Stassen, H. Nar, J.T. Kley, W. Wienen, U.J. Ries and P.J. Declerck, 2002. Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb. Haemost., 88: 137-143.
18. Glueck, C.J., N. Goldenberg, P. Wang and D. Aregawi, 2004. Ramifications of four concurrent thrombophilic mutations and one hypofibrinolytic mutation. Clin. Appl. Thromb Hemost., 10: 365-71.
19. Green, F. and S. Humphries, 1994. Genetic determinants of arterial thrombosis. Bailliere's Clin. Haematol., 7: 675-692.
20. Hanly, J.G., 2003. Antiphospholipid syndrome: An overview. CMAJ., 168: 1675-1682.
21. Henry, M., D.A. Tregouët, M.C. Alessi, M.F. Aillaud, S. Visvikis, G. Siest, L. Tiret and I. Juhan-Vague, 1998. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: A family study with part of the Stanislas cohort. Arterioscler. Thromb. Vasc. Boil., 18: 84-91.
22. Hoppensteadt, D., J. Cunanan, J.M. Walenga, M. Wilmer, M. Janssen, S. Kahn and J. Fareed, 2005. Laboratory and clinical validation of a new functional, plasma based assay for the detection of factor V Leiden: The Pefiakit ® APC-R factor V Leiden assay. J. Thromb. Haemost., Vol. 3, Supplement 1: Abstract
23. Kurkowska-Jastrzebska, I., W. Wicha, A. Dowzenko, B. Vertun-Baranowska, A. Pytlewski, R. Boguslawska and A. Czlonkowska, 2003. Concomitant heterozygous factor V Leiden mutation and homozygous prothrombin gene variant (G20210A) in patient with cerebral venous thrombosis. Med. Sci. Monit., 9: CS41-45.
24. Lane, D.A. and P.J. Grant, 2000. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood, 95: 1517-1532.
25. Lawrence, L.K. and M.D. Leung, 2005. Assessment of patients with thrombotic disorders. Primary clinical issues in thrombotic disorders. Section 5 chapter XIV Thrombotic disorders [www.acpmedicine.com].
26. Lopes, C., C. Dina, E. Durand and P. Froguel, 2003. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia, 46: 1284-1290.
27. Meroni, P.L., M. Moia, R.H. Derksen, A. Tincani, J.A. McIntyre, J.M. Arnout, T. Koike, J.C. Piette, M.A. Khamashta and Y. Shoenfeld, 2003. Venous thromboembolism. in the antiphospholipid syndrome: Management guidelines for secondary prophylaxis. Lupus, 12: 504-507.
28. Miller, S.A., D.D. Dykes and H.F. Plesky, 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl. Acid Res., 16: 1215.
29. Pegoraro, R.J. and N. Ranjith, 2005. Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction. Cardiovasc. J. S Afr., 16: 266-270.
30. Rand, J.H., 2003. The antiphospholipid syndrome. Ann. Rev. Med., 54: 409-424.
31. Sartori, M.T., B. Wiman, S. Vettore, F. Dazzi and A. Girolami, G.M. Patrassi, 1998. 4G/5G Polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep verious thrombosis. Thromb. Haemost., 80: 956-960.
32. Sartori, M.T., C. Danesin, G. Saggiorato, D. Tormene, P. Simioni, L. Spiezia, G.M. Patrassi and A. Girolami, 2003. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin. Applied Thromb. Hemost., 9: 299-307.
33. Segui, R., A. Estelles, Y. Mira, F. Espana, P. Villa, C. Falco, A. Vaya, S. Grancha, F. Ferrando and J. Aznar, 2000. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br. J. Haematol., 111: 122-128.
34. Sheppard, D.R., 2000. Activated protein C resistance: The most common risk factor for venous thromboembolism. J. Am. Board Fam. Prac., 13: 111-115.
35. Smith, A., C. Patterson, J. Yarnell, A. Rumley, Y. Ben-Shlomo and G. Lowe, 2005. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? Circulation., 112: 3080-3087.
36. Stiko, A., L. Hervio and D.J. Loskutoff, 2001. Plasminogen Activator Inhibitors. In: Haemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th Edn. Colman, R.W., J. Hirsh, V.J. Marder, A.W. Clowes and J.N. George (Eds.). Philadelphia, L.W.W. Com., Cha. 18, pp: 355-361.
37. Svensson, P.J. and B. Dahlback, 1994. Resistance to activated protein C as a basis for venous thrombosis. N. Eng. J. Med., 330: 517.
38. van der J.C. Bom, M.H. Bots and F. Haverkate, 1996. Reduced response to activaed proein C is associated with increased risk for cerebrovascular disease. Ann. Intl. Med., 125: 265-269.
39. Wu, O. and Z. Zhao, 2002. Inhibition of PAI-1, a new antithrombotic approach. Curr. Drug Targets Cardiovasc. Haematol. Disord., 2: 27-42.